Global capabilities
Delivering value beyond the test result
At Mayo Clinic Laboratories, laboratory medicine is about more than a test result — it’s about everything that contributes to providing answers for your patients. We develop individualized support solutions for each client that extend through all aspects of the relationship to ensure the delivery of answers, not just results.
Specialized testing areas include:
Global logistics and shipping
We develop unique relationships with each client to individualize logistics support, which is coordinated by a local team who ensures a seamless process before the first patient specimen is sent. Our specialists collaborate with packaging suppliers to create unique solutions that extend the stability of specimens traveling around the world.
These experts ensure specimens are handled carefully and efficiently through close connections to shipping carriers. The air carriers we work with are experienced with processing clinical specimens.
Optimized, expeditious processing
We recognize many medical conditions have a window of opportunity for the best possible outcomes. Our tests and processes are optimized to better serve patients and deliver results with outcomes in mind. We do not triage specimens across a network of labs or use a batch-testing business model. Result turnaround times are expedited by:
- Running tests continuously – your samples are processed alongside those from Mayo Clinic.
- A testing approach that incorporates comprehensive panels and algorithms when appropriate.
- Utilization of Lean and Six Sigma processes.
Reliable connectivity
We offer technology solutions to help our clients connect to us, including a secure online portal with interfacing capabilities that allows you to easily order tests and receive results. Our solutions include:
- Client-friendly test ordering through MayoLINK, which is available in eight languages.
- Expansive website with links to our open- access test catalog, which is updated daily and features comprehensive clinical information, including specimen requirements; clinical and interpretative information; performance; sample test reports; setup files; and pricing.
- 30 country-specific toll-free numbers.
News and updates
The latest
Dr. Bill Morice shares how clinical diagnostics are expanding to guide treatment and enable clinicians to target therapies more precisely.
Last year, when Brian Netzel was redeployed from Mayo Clinic's Biochemical Genetics Lab to a lab testing for COVID-19, he put his skills to work wherever they were needed — alongside hundreds of other Mayo staff doing the same as they battled the pandemic together.
Kevin Halling, M.D., Ph.D., explains how the MayoComplete Solid Tumor panel uses next-generation sequencing to assess 514 clinically significant, cancer-related genes for genetic alterations that offer insight on treatment effectivity.
A collaborative study between Mayo Clinic and the University of Illinois debunked the previous consensus about how kidney stones grow.
Part II of this series shows how a breakthrough discovery about how kidney stones form may open the way for new, unorthodox treatments. The discovery was made possible by joining University of Illinois’ geology and biology forces with Mayo Clinic’s urology and nephrology expertise.
This week’s research roundup features a study on therapeutic trials in adult FSGS and lessons learned for the road forward.
The following list includes updates posted to mayocliniclabs.com during the month of May.
COVID-19 weekly news: Mayo Clinic updates masking, in-person meeting guidance; brushing off the ‘social rust’ as COVID-19 restrictions ease and how patients are now permitted two visitors at Mayo Clinic Health system locations.
Managing an outreach laboratory requires more than just sound technical skills. It also requires an firm understanding of the various financial components that affect the way a lab operates and performs in order to demonstrate, and prove, the positive financial impact of an outreach program.
William Morice II, M.D., Ph.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic and president of Mayo Clinic Laboratories, hosts this episode of the "Answers From the Lab" podcast. He’s joined by Gianluca Pettiti, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific to discuss their organizations’ collaboration and its value for patients.
This week’s research roundup features a study on how RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis.
Dr. Hipp is a board-certified pathologist with fellowship training in pathology informatics, as well as artificial intelligence, machine, and deep-learning experience.
Top highlights include: Mayo Clinic updates to guidance for masking, information about the safety and efficacy of COVID-19 vaccines for children, and an expert podcast from Dr. Poland.